Michael J. Akers, PhD
Michael J. Akers, PhD, is a Pharmtech editorial advisory board (EAB) member.
Michael J. Akers, PhD
Senior Director,
Pharmaceutical R&D,
Baxter BioPharma Solutions
Micheal J. Akers is senior director of pharmaceutical research and development at Baxter BioPharma Solutions in Bloomington, Indiana. He leads the Baxter Center of Lyophilization Excellence. Akers is active in the AAPS and PDA organizations, where in the past he has served on their leadership boards as well as being a Fellow of the American Association of Pharmaceutical Scientists (AAPS). He also serves on the United States Pharmacopeia Parenteral Products Expert Committee.
Akers is editor-in-chief of Pharmaceutical Development and Technology. He has published more than 100 research articles, teaching articles, review articles and book chapters, including the Parenterals chapter for the 21st edition of Remington’s: The Science and Practice of Pharmacy. He has also authored/edited four books. He teaches several continuing education courses each year on the basics of sterile product science and technology. Akers received his PhD degree in Pharmaceutics from the University of Iowa College of Pharmacy.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
